| 1 |
33419165 | Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. | 2021 Jan 6 |
1 |
| 2 |
34011532 | Negative Regulation of Human Hepatic Constitutive Androstane Receptor by Cholesterol Synthesis Inhibition: Role of Sterol Regulatory Element Binding Proteins. | 2021 Aug |
1 |
| 3 |
34425670 | A Novel Splice Site Variant in the LDLRAP1 Gene Causes Familial Hypercholesterolemia | 2021 Sep 1 |
1 |
| 4 |
29665658 | Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model. | 2018 Nov |
1 |
| 5 |
26744986 | Mixed effects of OATP1B1, BCRP and NTCP polymorphisms on the population pharmacokinetics of pravastatin in healthy volunteers. | 2016 Sep |
1 |
| 6 |
26222708 | Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia. | 2015 Sep |
1 |
| 7 |
23907716 | Co-medication of pravastatin and paroxetine-a categorical study. | 2013 Nov |
1 |
| 8 |
22216116 | Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. | 2011 |
1 |
| 9 |
19923996 | HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study. | 2010 Feb |
1 |
| 10 |
19122443 | [Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet]. | 2009 Jan |
2 |
| 11 |
20409966 | A HMGCR polymorphism is associated with relations between blood pressure and urinary sodium and potassium ratio in the Epic-Norfolk Study. | 2009 Jul-Aug |
1 |
| 12 |
17391675 | Effect of pravastatin on the development of diabetes and adiponectin production. | 2008 Jan |
1 |
| 13 |
18383345 | Statin treatment of adult human glial progenitors induces PPAR gamma-mediated oligodendrocytic differentiation. | 2008 Jul |
1 |
| 14 |
18797167 | Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. | 2008 |
1 |
| 15 |
17439540 | SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. | 2007 Sep |
1 |
| 16 |
17563401 | Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. | 2007 Sep |
2 |
| 17 |
16359930 | Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease. | 2006 Feb |
1 |
| 18 |
16603852 | Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study. | 2006 Apr 24 |
1 |
| 19 |
16327254 | Lipids and stroke: the opportunity of lipid-lowering treatment. | 2005 |
1 |
| 20 |
16356805 | Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. | 2005 Dec |
1 |
| 21 |
15015196 | Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes. | 2004 Apr |
1 |
| 22 |
15116260 | Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis. | 2004 May |
1 |
| 23 |
15199031 | Pharmacogenetic study of statin therapy and cholesterol reduction. | 2004 Jun 16 |
1 |
| 24 |
15205608 | 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. | 2004 Jul |
1 |
| 25 |
12733694 | Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients. | 2003 Apr |
1 |
| 26 |
11831546 | Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. | 2002 Feb |
1 |
| 27 |
11906972 | Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. | 2002 Mar |
1 |
| 28 |
12032266 | A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. | 2002 Jun |
1 |
| 29 |
12039487 | Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin. | 2002 Jun 5 |
1 |
| 30 |
12433810 | Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. | 2002 Dec |
1 |
| 31 |
12459073 | [Comparative study of the impact of diet versus pravastatin on color vision in Brodman area 19 detected by computerized chromatic analysis (CARDIOCOLOUR Study)]. | 2002 Dec |
1 |
| 32 |
12652117 | Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors. | 2002 Sep |
1 |
| 33 |
11165421 | Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). | 2001 Feb |
1 |
| 34 |
11244205 | Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. | 2001 |
1 |
| 35 |
11276395 | Recent clinical trial highlights in hypertension. | 2001 Apr |
1 |
| 36 |
11318529 | Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population. | 2001 Mar |
1 |
| 37 |
11356905 | Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. | 2001 Jun |
1 |
| 38 |
11359999 | The in vitro inhibitory effect of tannin derivatives on 3-hydroxy-3-methylglutaryl-coenzyme a reductase on vero cells. | 2001 May |
1 |
| 39 |
11404165 | Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. | 2001 Jun |
1 |
| 40 |
11469968 | Hyperlipidemia in Chronic Cholestatic Liver Disease. | 2001 Apr |
1 |
| 41 |
11602546 | Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial. | 2001 Nov |
1 |
| 42 |
15989499 | The effect of HMG-CoA reductase inhibitors on chronic allograft rejection. | 2001 Apr |
1 |
| 43 |
10732240 | [Intensification in vivo of free radical oxidation of low density lipoproteins in plasma from patients with myocardial ischemia treated by HMG-CoA-reductase pravastatin and suppression of lipid peroxidation by ubiquinone Q10]. | 2000 Feb |
1 |
| 44 |
10952477 | Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. | 2000 Jun |
1 |
| 45 |
11030795 | Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. | 2000 Oct |
1 |
| 46 |
11074211 | Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. | 2000 Nov 15 |
1 |
| 47 |
10381291 | Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. | 1999 May |
1 |
| 48 |
10399998 | Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. | 1999 Jul |
1 |
| 49 |
10490896 | Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. | 1999 Oct |
1 |
| 50 |
10554675 | Prevention of mortality from coronary heart disease with pravastatin. | 1999 Oct |
1 |